Form 8-K - Current report:
SEC Accession No. 0001213900-25-043733
Filing Date
2025-05-15
Accepted
2025-05-15 08:40:34
Documents
13
Period of Report
2025-05-14
Items
Item 5.08: Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ea0242287-8k_adial.htm   iXBRL 8-K 28820
  Complete submission text file 0001213900-25-043733.txt   202548

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE adil-20250514.xsd EX-101.SCH 3005
3 XBRL LABEL FILE adil-20250514_lab.xml EX-101.LAB 34239
4 XBRL PRESENTATION FILE adil-20250514_pre.xml EX-101.PRE 22352
15 EXTRACTED XBRL INSTANCE DOCUMENT ea0242287-8k_adial_htm.xml XML 3659
Mailing Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901
Business Address 1180 SEMINOLE TRAIL SUITE 495 CHARLOTTESVILLE VA 22901 434-422-9800
ADIAL PHARMACEUTICALS, INC. (Filer) CIK: 0001513525 (see all company filings)

EIN.: 800667150 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38323 | Film No.: 25948977
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)